This is a working overview of pituitary axis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
== History == The concept of hydrogen bonding once was challenging. Linus Pauling credits T. S. Moore and T. F. Winmill with the first mention of the hydrogen bond, in 1912. Moore and Winmill used the hydrogen bond to account for the fact that trimethylammonium hydroxide is a weaker base than tetramethylammonium hydroxide. The description of hydrogen bonding in its better-known setting, water, came some years later, in 1920, from Latimer and Rodebush. In that paper, Latimer and Rodebush cited the work of a fellow scientist at their laboratory, Maurice Loyal Huggins, saying, "Mr. Huggins of this laboratory in some work as yet unpublished, has used the idea of a hydrogen kernel held between two atoms as a theory in regard to certain organic compounds."
Like other cephalopods, octopuses have camera-like eyes. Colour vision appears to vary from species to species, for example, it is present in A. aegina but absent in O. vulgaris. Opsins in the skin respond to different wavelengths of light and help the animals choose a colouration that matches the surroundings and camouflages them; chromatophores in the skin can respond to light independently of the eyes. An alternative hypothesis is that cephalopod eyes in species that only have a single photoreceptor protein may use chromatic aberration to turn monochromatic vision into colour vision, though this lowers image quality. This would explain pupils shaped like the letter "U", the letter "W", or a dumbbell, as well as the need for colourful mating displays. Attached to the optic capsules are two organs called statocysts (sac-like structures containing a mineralised mass and sensitive hairs), that allow the octopus to sense the orientation of its body, relative to both gravity and time (angular acceleration). An autonomic response keeps the octopus's eyes oriented so that the pupil is always horizontal. Octopuses may also use the statocyst to hear. The common octopus can hear sounds between 400 Hz and 1000 Hz, and hears best at 600 Hz. Octopuses have an excellent somatosensory system. Their suction cups are equipped with chemoreceptors so they can taste what they touch. Octopus arms move easily because the sensors recognise octopus skin and prevent self-attachment. Octopuses appear to have poor proprioceptive sense and must see their arms to keep track of their position.
=== Other nervous system side effects === Nervous-system effects include insomnia, restlessness, and rarely, seizure, convulsions, and psychosis. Other rare and serious adverse events have been observed with varying degrees of evidence for causation.
Sources: en.wikipedia.org
=== 28 October === General al-Burhan confirmed that the SAF had withdrawn from El Fasher, confirming RSF control over the city and ending the Siege of El Fasher. At least 2,500 civilians were massacred by the RSF over the following days, including more than 460 people in the Saudi hospital.
In wound-healing in urodeles it is the quick response of anti-inflammatory macrophages which have been shown to be key to their regeneration capabilities. In one study, it was found that limbs would not regenerate in those urodeles with depleted macrophages and instead would scar with permanent loss of functionality. Knowing how regeneration occurs in animals such as these may have great implications for how wound-healing is tackled in medicine and research has been aimed at this area, as a result.
Imvescor was the parent company of the restaurant chains Scores, Pizza Delight, Mikes, Baton Rouge with a history that goes back to 1968. It was known as Pizza Delight Corporation until 2007, when the name was changed to Imvescor. As Pizza Delight Corporation, the company purchased Mikes in 2000 for $14.5 million, Quebec company Scores Rotisserie Barbecue and Ribs in 2005 for $32 million and Baton Rouge Restaurants. Headquartered in Moncton, the company was in charge of 259 restaurants across Canada (101 Pizza Delight, 91 Mikes, 39 Scores, and 28 Baton Rouge). Imvescor used to be a privately owned corporation that held the licence for the trademark and intellectual property of the four restaurants by PDM Royalties Income Fund. In 2009, the income fund and Imvescor combined their businesses into a new corporation called Imvescor Restaurant Group Inc. The four restaurant chains employed over 10,000 people. Total system sales in 2009 were $324.8 million. Imvescor is now owned by MTY Food Group, after being acquired in December 2017.
=== Dating === Dating Lindow Man is difficult as samples from the body and surrounding peat have produced dates spanning a 900-year period. Although the peat encasing Lindow Man has been radiocarbon dated to about 300 BC, Lindow Man himself has a different date. Early tests at different laboratories returned conflicting dates for the body; later tests suggested a date between 2 BC and 119 AD. There has been a tendency to ascribe the body to the Iron Age period rather than Roman because of the interpretation that Lindow Man's death may have been a ritual sacrifice or execution. Explanations for why the peat in which he was found is much older have been sought. Archaeologist P. C. Buckland suggests that as the stratigraphy of the peat appears undisturbed, Lindow Man may have been deposited into a pool that was already some 300 years old. Geographer K. E. Barber has argued against this hypothesis, saying that pools at Lindow Moss would have been too shallow, and suggests that the peat may have been peeled back to allow the burial and then replaced, leaving the stratigraphy apparently undisturbed.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.